Impax Labs, retailers ink midtrial settlement in Solodyn 'pay-for-delay' case

contract
Impax agreed to settle with a group of retailers in Solodyn antitrust litigation. (Pixabay)

In pharma's second "pay-for-delay" settlement in under a week, a class of retailers have dropped claims that Impax Labs made an illegal deal to delay the launch of its generic version of Valeant's acne drug Solodyn. 

The agreement with retailers such as Walgreens, Kroger and CVS stipulates that each side will pay its own legal fees, a court filing stated; other terms weren't disclosed. A spokesperson for Impax didn't immediately respond to a request for comment.

This week's development follows another settlement inked by Impax earlier this month—worth $35 million—with direct purchasers, according to court filings. Valeant, which acquired Solodyn in its 2012 Medicis buyout, last month disclosed its own $58 million settlement related to the allegations.

Sponsored by Lubrizol Life Science

[Webinar] Cannabinoid Formulation - from Farm to Pharma

Wednesday, June 24, 2020 | 12pm ET / 9am PT

A handful of cannabinoid-based pharmaceutical products are on the market today, and an ever-growing number are in the global development pipeline. This webinar will explore key considerations in developing cannabinoid-based pharmaceutical products, including an overview of global pharmaceutical cannabinoid usage today, common challenges formulating with CBD and other cannabinoids, and more.

Despite the settlements, the Solodyn litigation still includes claims by insurers and consumers, Reuters notes. The case has been at trial since mid-March, according to the court. 

The lawsuit claims Solodyn manufacturer Medicis and Impax violated antitrust laws with a 2008 pay-for-delay deal. Medicis forked over $40 million, plus more in "milestones," to Impax, which in return dropped a patent lawsuit and delayed its generic entrant, the lawsuit says. Impax has denied wrongdoing, according to Reuters. 

RELATED: Endo, Teva join $270M deal to wrap up Lidoderm pay-for-delay lawsuit 

So-called pay-for-delay deals have long irked federal officials and lawmakers, and the FTC has been working to get tough on them in recent years. In 2013, the Supreme Court ruled that the deals aren't always lawful, undercutting a defense by drugmakers that they are legal. 

Impax's deal follows a settlement last week by Endo, Teva and Japan's Teikoku Seiyaku to wrap up pay-for-delay claims over generic Lidoderm. That arrangement is worth $270 million.

RELATED: Bisaro steers Impax to $6.4B Amneal merger, creating fifth-largest U.S. generics company 

Meanwhile, Impax is working to merge with Amneal in response to intense pricing pressure that's weighing on the generic industry. The company appointed former Actavis CEO as its helmsman last March and in October agreed to the $6.4 billion Amneal merger. Now, the drugmaker says it's on track to close the deal in the second quarter of this year. 

Suggested Articles

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.

Alexion and Amgen reached a deal to put off a biosimilar challenger to Alexion's blockbuster rare disease med Soliris until March 2025.

A top adviser for the Trump administration is calling on Congress to push for more manufacturing in Puerto Rico.